Company intelligence / Profile preview

Therabel

Levallois‐Perret, Francetherabel.com ↗

Ownership: Private
Employees: ~82
Development stage: Commercial

Overview

Therabel is a privately-owned European pharmaceutical company established in 1945. It specializes in partnering with other pharma firms to commercialize and distribute therapeutic solutions across Europe. Its own pipeline includes small molecule drugs for cardiovascular and CNS conditions, with some programs reaching approval or commercial status. The majority of its portfolio comes from collaborations rather than internal R&D.

Therapeutic areas: Men's HealthCardiovascularPsychiatry
Modalities: Small moleculeOther modalities possible via partnerships
Industry: Biotech

Drug pipeline

1 asset

Prostaserene

Unknown

Partnerships

Numerous partnerships with pharmaceutical companies for product commercialization across Europe; specific partners not disclosed publicly.

Beyond the preview

Go deeper on Therabel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Therabel.

Explore the full profile